Physician profile
Richard Clark
NPI 1073718052
$4,961.50
in general payments reported to CMS, 2019-2025
24 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $1,056 · 2021: $989 · 2022: $913 · 2023: $740 · 2024: $624 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,006.39 | 2019-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $622.69 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $619.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $213.75 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $196.33 | 2021-2023 | Xarelto |
| Solta Medical, A Division of Bausch Health US, LLC | $167.39 | 2024 | |
| Pfizer INC. | $160.76 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $151.04 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $144.53 | 2023-2024 | |
| Edwards Lifesciences Corporation | $120.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.69 | 2021-2023 | Eliquis |
| Kestra Medical Technology Services, INC. | $55.61 | 2022-2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $43.48 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $37.70 | 2024 | Onpattro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.56 | 2022-2024 | Repatha |
| Abiomed | $34.03 | 2023 | Impella |
| Philips North America LLC | $30.99 | 2020 | |
| Heartflow, INC. | $28.29 | 2025 | |
| Novo Nordisk INC | $21.36 | 2024 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $15.47 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2021 | |
| Bardy Diagnostics, INC. | $4.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.